Adaptive Design Study for Safety and Efficacy of Treatment Regimens With SM-020 in Subjects With Seborrheic Keratosis
Status:
Recruiting
Trial end date:
2022-06-15
Target enrollment:
Participant gender:
Summary
This is a first-in-humans adaptive design open label trial to explore the safety and efficacy
of SM-020. Multiple dosing cohorts will be enrolled. The first cohort will have a two-week
treatment period of twice daily applications followed by a four-week follow-up period. Based
on the results at any time from the first and subsequent cohorts, additional cohorts will
explore different dosing regimens.